Castle Biosciences Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Castle Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $43.56. The average 1-year stock price forecast is 77.36% higher than the current stock price, while the lowest is $35 (+42.51%) and the highest is $52 (+111.73%).

Price Target: $43.56 (+77.36%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$35	$43.56	$43	$52
Change	+42.51%	+77.36%	+75.08%	+111.73%

Analyst Ratings

The average analyst rating for Castle Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	8	8	8	8	9	9
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	9	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Max Masucci Roth MKM	Roth MKM	Buy Initiates $40	Buy	Initiates	$40	+62.87%	Jun 24, 2026
Paul Knight KeyBanc	KeyBanc	Buy Maintains $50 → $35	Buy	Maintains	$50 → $35	+42.51%	May 29, 2026
Mark Massaro BTIG	BTIG	Buy Reiterates $50 → $40	Buy	Reiterates	$50 → $40	+62.87%	May 13, 2026
Catherine Ramsey Schulte Robert W. Baird	Robert W. Baird	Buy Maintains $44 → $43	Buy	Maintains	$44 → $43	+75.08%	May 7, 2026
Kyle Mikson CFA Canaccord Genuity	Canaccord Genuity	Buy Maintains $40	Buy	Maintains	$40	+62.87%	May 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

352.69M

from 344.23M

2.46%

from 344.23M

Revenue Next Year

393.47M

from 352.69M

11.56%

from 352.69M

EPS This Year

-1.40

from -0.83

EPS Next Year

-0.93

from -1.40

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	94.09M	137.04M	219.79M	332.07M	344.23M	352.69M
Revenue Growth	50.18%	45.65%	60.38%	51.09%	3.66%	2.46%
Gross Profit	78.26M	105.03M	174.81M	271.86M	273.20M	261.43M
Gross Margin	83.18%	76.64%	79.53%	81.87%	79.37%	74.13%
Operating Income	-40.08M	-91.14M	-67.98M	8.67M	-22.71M	-57.28M
Net Income	-31.29M	-67.14M	-57.47M	18.25M	-24.16M	-43.46M
EPS	-	-	-	-	-0.83	-1.40
Free Cash Flow	-5.03M	-14.69M	818.50K	29.45M	41.21M	-25.50M
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	355.0M
Avg	352.7M
Low	350.2M

Revenue Growth

Revenue Growth	2026	2027	2028
High	3.1%
Avg	2.5%
Low	1.7%

EPS Forecast

EPS	2026	2027	2028
High	-0.84
Avg	-1.40
Low	-1.74

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-